USTR Discusses TRIPS Waiver With Pfizer CEO, AstraZeneca Official
U.S. Trade Representative Katherine Tai published a readout of video calls she had with the leader of AstraZeneca's U.S. business and Pfizer's CEO on whether there should be a waiver of the World Trade Organization's agreement on Trade-Related Aspects of…
Sign up for a free preview to unlock the rest of this article
Timely, relevant coverage of court proceedings and agency rulings involving tariffs, classification, valuation, origin and antidumping and countervailing duties. Each day, Trade Law Daily subscribers receive a daily headline email, in-depth PDF edition and access to all relevant documents via our trade law source document library and website.
Intellectual Property Rights (TRIPS). The readouts did not say what either the government or companies' positions are on a TRIPS waiver, and during a background call on aid to India to combat its surge of cases and deaths, an official also sidestepped a question on the waiver. The readouts said that Tai “emphasized her commitment to working with WTO members on a global pandemic response, including the role of developing countries in any effective solution that addresses critical gaps in global production and distribution of vaccines”; and that the Pfizer CEO also wants to improve global access to the vaccine, and he discussed “how trade policy could help address the challenges of increasing vaccine production and distribution around the world.”